X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (1) 1
analysis (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
bevacizumab - administration & dosage (1) 1
bevacizumab - adverse effects (1) 1
bevacizumab - therapeutic use (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
cancer patients (1) 1
cancer therapies (1) 1
care and treatment (1) 1
cetuximab (1) 1
chemotherapy (1) 1
colorectal cancer (1) 1
colorectal neoplasms - drug therapy (1) 1
colorectal neoplasms - genetics (1) 1
colorectal neoplasms - mortality (1) 1
colorectal neoplasms - pathology (1) 1
cytotoxicity (1) 1
disease-free survival (1) 1
dna mutational analysis (1) 1
drug administration schedule (1) 1
end-point (1) 1
female (1) 1
fluorouracil (1) 1
fluorouracil - administration & dosage (1) 1
guidelines (1) 1
hematology, oncology and palliative medicine (1) 1
humans (1) 1
index medicus (1) 1
infusions, intravenous (1) 1
intention to treat analysis (1) 1
italy (1) 1
kaplan-meier estimate (1) 1
kras (1) 1
leucovorin (1) 1
leucovorin - administration & dosage (1) 1
male (1) 1
metastasis (1) 1
middle aged (1) 1
mutation (1) 1
neoplasm metastasis (1) 1
oncology (1) 1
organoplatinum compounds - administration & dosage (1) 1
ovarian cancer (1) 1
patient outcomes (1) 1
progression-free survival (1) 1
proportional hazards models (1) 1
proto-oncogene proteins - genetics (1) 1
proto-oncogene proteins b-raf - genetics (1) 1
proto-oncogene proteins p21 (1) 1
ras mutations (1) 1
ras proteins - genetics (1) 1
surrogate (1) 1
time factors (1) 1
treatment outcome (1) 1
trial (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.